{
    "clinical_study": {
        "@rank": "101022", 
        "brief_summary": {
            "textblock": "To study the anti-HIV activity of the various doses of Ro 24-7429 monotherapy based on\n      virologic and immunologic endpoints. To study the safety and tolerance of Ro 24-7429. To\n      explore relationships between exposure to Ro 24-7429 and its metabolites and antiviral\n      activity and drug toxicity. To determine a safe, tolerable, and active dose regimen of Ro\n      24-7429, and to make preliminary observations of Ro 24-7429 in combination with another\n      antiretroviral nucleoside.\n\n      The HIV genome contains a number of genes that regulate viral replication. Control of the\n      activity of these genes and their encoded proteins represents a potential target for\n      development of new antiretroviral drugs. The tat (transactivator of transcription of HIV)\n      antagonist Ro 24-7429 is the first compound for clinical testing that utilizes this approach\n      for therapy of HIV infection."
        }, 
        "brief_title": "A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "The HIV genome contains a number of genes that regulate viral replication. Control of the\n      activity of these genes and their encoded proteins represents a potential target for\n      development of new antiretroviral drugs. The tat (transactivator of transcription of HIV)\n      antagonist Ro 24-7429 is the first compound for clinical testing that utilizes this approach\n      for therapy of HIV infection.\n\n      Ninety-six patients (four treatment arms of 24 patients each) are randomized to receive oral\n      Ro 24-7429 at 1 of 3 doses or nucleoside control (either zidovudine or didanosine). The\n      study will be blinded only for the arms receiving Ro 24-7429. Treatment continues for 12\n      weeks. After 12 weeks, patients on the nucleoside control arm receive the highest tolerated\n      dose of Ro 24-7429 in addition to their nucleoside."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Chemoprophylaxis for P. carinii pneumonia, TB, and mucocutaneous candidiasis.\n\n          -  Methadone maintenance.\n\n          -  Hormonal contraceptives.\n\n        Patients must have:\n\n          -  HIV-1 seropositivity.\n\n          -  CD4 count 50 - 500 cells/mm3.\n\n          -  Life expectancy of at least 24 weeks.\n\n          -  Stable weight (+/- 2 kg) by 28 days prior to study entry (by history).\n\n        NOTE:\n\n          -  At least 50 percent of patients must be p24 antigen positive (>= 50 pg/ml).\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Known or suspected hypersensitivity to benzodiazepines.\n\n          -  Presence of any malignancy other than basal cell carcinoma or limited cutaneous\n             Kaposi's sarcoma (defined as no more than five lesions with no mucosal involvement).\n\n          -  Ongoing diarrhea, defined as more than 2 liquid stools per day.\n\n          -  History, physical exam, or laboratory results consistent with a subclinical\n             AIDS-defining opportunistic infection.\n\n          -  Grade 2 or greater signs and symptoms of AIDS Dementia Complex.\n\n          -  Evidence of clinically significant cardiac, respiratory, hepatic, gastrointestinal,\n             endocrine, hematologic, psychiatric, neurologic, dermatologic, or allergic disease.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Chronic suppressive therapy for CMV, MAI, toxoplasmosis, cryptococcosis,\n             cryptosporidiosis, coccidioidomycosis, and histoplasmosis.\n\n          -  ddC, ddI, AZT (except for control groups) or other experimental antiretrovirals or\n             immunomodulating agents.\n\n          -  Other medications excluded from the study.\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of serious adverse reactions to benzodiazepines.\n\n          -  History of intolerance to AZT at 600 mg/day or less or ddI at 400 mg/day or less.\n\n          -  History of unexplained fever, defined as a temperature of 38.5 deg C or greater with\n             or without night sweats for more than 7 of the past 28 days.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Benzodiazepines within 14 days prior to study entry.\n\n        Active drug or alcohol abuse that would interfere with study compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": "96", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000760", 
            "org_study_id": "ACTG 213", 
            "secondary_id": "NV14224A"
        }, 
        "intervention": [
            {
                "intervention_name": "Ro 24-7429", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Didanosine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Didanosine", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Didanosine", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents", 
            "Zidovudine", 
            "Gene Products, tat"
        ], 
        "lastchanged_date": "July 31, 2008", 
        "link": [
            {
                "description": "Click here for more information about Zidovudine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
            }, 
            {
                "description": "Click here for more information about Didanosine", 
                "url": "http://www.aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=16"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92103"
                    }, 
                    "name": "UCSD"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21205"
                    }, 
                    "name": "Johns Hopkins Hosp"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Harvard (Massachusetts Gen Hosp)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44106"
                    }, 
                    "name": "Case Western Reserve Univ"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection", 
        "overall_official": [
            {
                "last_name": "Richman DD", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Haubrich R", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "PMID": "7594660", 
                "citation": "Haubrich RH, Flexner C, Lederman MM, Hirsch M, Pettinelli CP, Ginsberg R, Lietman P, Hamzeh FM, Spector SA, Richman DD. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J Infect Dis. 1995 Nov;172(5):1246-52."
            }, 
            {
                "citation": "Haubrich RH. A randomized study of safety, tolerance, pharmacokinetics, and activity of oral Ro 24-7429 (TAT antagonist) in patients with HIV infection. The ACTG 213 Team. Int Conf AIDS. 1993 Jun 6-11;9(1):69 (abstract no WS-B26-5)"
            }, 
            {
                "PMID": "9041402", 
                "citation": "Lathey JL, Marschner IC, Kabat B, Spector SA. Deterioration of detectable human immunodeficiency virus serum p24 antigen in samples stored for batch testing. J Clin Microbiol. 1997 Mar;35(3):631-5."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000760"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 1998"
    }, 
    "geocoordinates": {
        "Case Western Reserve Univ": "41.499 -81.695", 
        "Harvard (Massachusetts Gen Hosp)": "42.358 -71.06", 
        "Johns Hopkins Hosp": "39.29 -76.612", 
        "UCSD": "32.715 -117.157"
    }
}